Pakeeran Siriratnam

55 Commercial Road
Melbourne, VIC 3004, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Clinical Prognostic Factors Associated With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Multicenter Cohort Study.

Clinical Prognostic Factors Associated With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Multicenter Cohort Study.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: August 31, 2026

Modern diagnosis and treatment of multiple sclerosis: advances, challenges, and future directions.

Modern diagnosis and treatment of multiple sclerosis: advances, challenges, and future directions.

Journal: Autoimmunity reviews

Published: May 11, 2026

Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.

Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.

Journal: Neurology

Published: March 05, 2026

Timing for Starting Antiseizure Medication Withdrawal After Epilepsy Surgery in Adults.

Timing for Starting Antiseizure Medication Withdrawal After Epilepsy Surgery in Adults.

Journal: Neurology

Published: January 27, 2026

Inter-attack serum GFAP and NfL remain stable over 9 years in AQP4 IgG NMOSD.

Inter-attack serum GFAP and NfL remain stable over 9 years in AQP4 IgG NMOSD.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: January 21, 2026

Advances in the therapeutic landscape for neuromyelitis optica spectrum disorder.

Advances in the therapeutic landscape for neuromyelitis optica spectrum disorder.

Journal: Expert review of neurotherapeutics

Published: September 18, 2025

Patients with rheumatological diseases should routinely be tested for aquaporin-4 (AQP4) antibodies: No.

Patients with rheumatological diseases should routinely be tested for aquaporin-4 (AQP4) antibodies: No.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 25, 2025

A first report of progressive multifocal leukoencephalopathy in childhood-onset NMOSD.

A first report of progressive multifocal leukoencephalopathy in childhood-onset NMOSD.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: April 18, 2025

Rituximab as First-Line Compared to Escalation Immunotherapy Is Associated With Lower Disability Accumulation in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder: A Multicenter Cohort Study From Germany and the United Kingdom.

Rituximab as First-Line Compared to Escalation Immunotherapy Is Associated With Lower Disability Accumulation in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder: A Multicenter Cohort Study From Germany and the United Kingdom.

Journal: European journal of neurology

Published: March 01, 2025

Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study.

Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study.

Journal: Journal of neurology

Published: January 06, 2025

Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD.

Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD.

Journal: Neurology

Published: November 19, 2024

Is a Benign Disease Course Possible in Untreated AQP4-IgG NMOSD?

Is a Benign Disease Course Possible in Untreated AQP4-IgG NMOSD?

Journal: European journal of neurology

Published: October 25, 2024

Showing 1-12 of 31

Last Updated: 09/26/2026